Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: A report from the soft tissue sarcoma committee of the children's oncology group

R. Beverly Raney, David O. Walterhouse, Jane L Meza, Richard J. Andrassy, John C. Breneman, William M. Crist, Harold M. Maurer, William H. Meyer, David M. Parham, James R. Anderson

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Purpose: Patients with localized, grossly resected, or gross residual (orbital only) embryonal rhabdomyosarcoma (ERMS) had 5-year failure-free survival (FFS) rates of 83% and overall survival rates of 95% on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III/IV. IRSG D9602 protocol (1997 to 2004) objectives were to decrease toxicity in similar patients by reducing radiotherapy (RT) doses and eliminating cyclophosphamide for the lowest-risk patients. Patients and Methods: Subgroup A patients (lowest risk, with ERMS, stage 1 group I/IIA, stage 1 group III orbit, stage 2 group I) received vincristine plus dactinomycin (VA). Subgroup B patients (ERMS, stage 1 group IIB/C, stage group III nonorbit, stage 2 group II, stage 3 group I/II) received VA plus cyclophosphamide. Patients in group II/III received RT. Compared with IRS-IV, doses were reduced from 41.4 to 36 Gy for stage 1 group IIA patients and from 50 or 59 to 45 Gy for group III orbit patients. Results: Estimated 5-year FFS rates were 89% (95% CI, 84% to 92%) for subgroup A patients (n = 264) and 85% (95% CI, 74%, 91%) for subgroup B patients (n = 78); median follow-up: 5.1 years. Estimated 5-year FFS rates were 81% (95% CI, 68% to 90%) for patients with stage 1 group IIA tumors (n = 62) and 86% (95% CI, 76% to 92%) for patients with group III orbit tumors (n = 77). Conclusion: Five-year FFS and OS rates were similarto those observed in comparable IRS-III patients, including patients receiving reduced RT doses, but were lower than in comparable IRS-IV patients receiving VA plus cyclophosphamide. Five-year FFS rates were similar among subgroups A and B patients.

Original languageEnglish (US)
Pages (from-to)1312-1318
Number of pages7
JournalJournal of Clinical Oncology
Volume29
Issue number10
DOIs
StatePublished - Apr 1 2011

Fingerprint

Embryonal Rhabdomyosarcoma
Rhabdomyosarcoma
Dactinomycin
Vincristine
Sarcoma
Cyclophosphamide
Radiotherapy
Survival Rate
Orbit

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma : A report from the soft tissue sarcoma committee of the children's oncology group. / Raney, R. Beverly; Walterhouse, David O.; Meza, Jane L; Andrassy, Richard J.; Breneman, John C.; Crist, William M.; Maurer, Harold M.; Meyer, William H.; Parham, David M.; Anderson, James R.

In: Journal of Clinical Oncology, Vol. 29, No. 10, 01.04.2011, p. 1312-1318.

Research output: Contribution to journalArticle

@article{baa68cf92ef54a978793f4dce5feb5d7,
title = "Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: A report from the soft tissue sarcoma committee of the children's oncology group",
abstract = "Purpose: Patients with localized, grossly resected, or gross residual (orbital only) embryonal rhabdomyosarcoma (ERMS) had 5-year failure-free survival (FFS) rates of 83{\%} and overall survival rates of 95{\%} on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III/IV. IRSG D9602 protocol (1997 to 2004) objectives were to decrease toxicity in similar patients by reducing radiotherapy (RT) doses and eliminating cyclophosphamide for the lowest-risk patients. Patients and Methods: Subgroup A patients (lowest risk, with ERMS, stage 1 group I/IIA, stage 1 group III orbit, stage 2 group I) received vincristine plus dactinomycin (VA). Subgroup B patients (ERMS, stage 1 group IIB/C, stage group III nonorbit, stage 2 group II, stage 3 group I/II) received VA plus cyclophosphamide. Patients in group II/III received RT. Compared with IRS-IV, doses were reduced from 41.4 to 36 Gy for stage 1 group IIA patients and from 50 or 59 to 45 Gy for group III orbit patients. Results: Estimated 5-year FFS rates were 89{\%} (95{\%} CI, 84{\%} to 92{\%}) for subgroup A patients (n = 264) and 85{\%} (95{\%} CI, 74{\%}, 91{\%}) for subgroup B patients (n = 78); median follow-up: 5.1 years. Estimated 5-year FFS rates were 81{\%} (95{\%} CI, 68{\%} to 90{\%}) for patients with stage 1 group IIA tumors (n = 62) and 86{\%} (95{\%} CI, 76{\%} to 92{\%}) for patients with group III orbit tumors (n = 77). Conclusion: Five-year FFS and OS rates were similarto those observed in comparable IRS-III patients, including patients receiving reduced RT doses, but were lower than in comparable IRS-IV patients receiving VA plus cyclophosphamide. Five-year FFS rates were similar among subgroups A and B patients.",
author = "Raney, {R. Beverly} and Walterhouse, {David O.} and Meza, {Jane L} and Andrassy, {Richard J.} and Breneman, {John C.} and Crist, {William M.} and Maurer, {Harold M.} and Meyer, {William H.} and Parham, {David M.} and Anderson, {James R.}",
year = "2011",
month = "4",
day = "1",
doi = "10.1200/JCO.2010.30.4469",
language = "English (US)",
volume = "29",
pages = "1312--1318",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma

T2 - A report from the soft tissue sarcoma committee of the children's oncology group

AU - Raney, R. Beverly

AU - Walterhouse, David O.

AU - Meza, Jane L

AU - Andrassy, Richard J.

AU - Breneman, John C.

AU - Crist, William M.

AU - Maurer, Harold M.

AU - Meyer, William H.

AU - Parham, David M.

AU - Anderson, James R.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Purpose: Patients with localized, grossly resected, or gross residual (orbital only) embryonal rhabdomyosarcoma (ERMS) had 5-year failure-free survival (FFS) rates of 83% and overall survival rates of 95% on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III/IV. IRSG D9602 protocol (1997 to 2004) objectives were to decrease toxicity in similar patients by reducing radiotherapy (RT) doses and eliminating cyclophosphamide for the lowest-risk patients. Patients and Methods: Subgroup A patients (lowest risk, with ERMS, stage 1 group I/IIA, stage 1 group III orbit, stage 2 group I) received vincristine plus dactinomycin (VA). Subgroup B patients (ERMS, stage 1 group IIB/C, stage group III nonorbit, stage 2 group II, stage 3 group I/II) received VA plus cyclophosphamide. Patients in group II/III received RT. Compared with IRS-IV, doses were reduced from 41.4 to 36 Gy for stage 1 group IIA patients and from 50 or 59 to 45 Gy for group III orbit patients. Results: Estimated 5-year FFS rates were 89% (95% CI, 84% to 92%) for subgroup A patients (n = 264) and 85% (95% CI, 74%, 91%) for subgroup B patients (n = 78); median follow-up: 5.1 years. Estimated 5-year FFS rates were 81% (95% CI, 68% to 90%) for patients with stage 1 group IIA tumors (n = 62) and 86% (95% CI, 76% to 92%) for patients with group III orbit tumors (n = 77). Conclusion: Five-year FFS and OS rates were similarto those observed in comparable IRS-III patients, including patients receiving reduced RT doses, but were lower than in comparable IRS-IV patients receiving VA plus cyclophosphamide. Five-year FFS rates were similar among subgroups A and B patients.

AB - Purpose: Patients with localized, grossly resected, or gross residual (orbital only) embryonal rhabdomyosarcoma (ERMS) had 5-year failure-free survival (FFS) rates of 83% and overall survival rates of 95% on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III/IV. IRSG D9602 protocol (1997 to 2004) objectives were to decrease toxicity in similar patients by reducing radiotherapy (RT) doses and eliminating cyclophosphamide for the lowest-risk patients. Patients and Methods: Subgroup A patients (lowest risk, with ERMS, stage 1 group I/IIA, stage 1 group III orbit, stage 2 group I) received vincristine plus dactinomycin (VA). Subgroup B patients (ERMS, stage 1 group IIB/C, stage group III nonorbit, stage 2 group II, stage 3 group I/II) received VA plus cyclophosphamide. Patients in group II/III received RT. Compared with IRS-IV, doses were reduced from 41.4 to 36 Gy for stage 1 group IIA patients and from 50 or 59 to 45 Gy for group III orbit patients. Results: Estimated 5-year FFS rates were 89% (95% CI, 84% to 92%) for subgroup A patients (n = 264) and 85% (95% CI, 74%, 91%) for subgroup B patients (n = 78); median follow-up: 5.1 years. Estimated 5-year FFS rates were 81% (95% CI, 68% to 90%) for patients with stage 1 group IIA tumors (n = 62) and 86% (95% CI, 76% to 92%) for patients with group III orbit tumors (n = 77). Conclusion: Five-year FFS and OS rates were similarto those observed in comparable IRS-III patients, including patients receiving reduced RT doses, but were lower than in comparable IRS-IV patients receiving VA plus cyclophosphamide. Five-year FFS rates were similar among subgroups A and B patients.

UR - http://www.scopus.com/inward/record.url?scp=79954446661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954446661&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.30.4469

DO - 10.1200/JCO.2010.30.4469

M3 - Article

C2 - 21357783

AN - SCOPUS:79954446661

VL - 29

SP - 1312

EP - 1318

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -